The following is a summary of current U.S. prescribing information and is not an individualized prescription.
| Treatment setting | Labeled abiraterone regimen |
| Metastatic CRPC | 1,000 mg once daily with prednisone 5 mg twice daily |
| Metastatic high-risk CSPC | 1,000 mg once daily with prednisone 5 mg once daily |
| 250 mg tablet equivalent | Four 250 mg tablets provide 1,000 mg |
Empty-stomach administration
Abiraterone acetate should be taken as a single daily dose on an empty stomach. Current U.S. labeling specifies no food for 2 hours before and 1 hour after the dose. Tablets should be swallowed whole with water.
Androgen-deprivation therapy
Patients receiving abiraterone should also receive a GnRH analog or have undergone bilateral orchiectomy according to current U.S. labeling.
Hepatic impairment
Patients with baseline moderate hepatic impairment require a lower starting dose under current U.S. labeling. Severe hepatic impairment is not treated in the same manner and requires careful consideration of the applicable prescribing information.
Hepatotoxicity during treatment
If clinically significant liver toxicity develops, abiraterone may need to be withheld. Treatment can sometimes be resumed at a reduced dose after recovery, while severe hepatotoxicity may require permanent discontinuation.
Dose changes
Dose modifications should be made by the treating healthcare professional based on the adverse reaction, liver function and applicable product labeling.
Important distinction
Abirapro 250 mg describes the strength of one tablet; it does not necessarily mean that 250 mg once daily is the standard dose for prostate cancer. Current U.S. labeled treatment commonly uses a total daily abiraterone acetate dose of 1,000 mg, equivalent to four 250 mg tablets.